BIRMINGHAM, Ala., Oct. 7, 2025 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will report results for its third quarter ended Sept. 30, 2025, after the market closes on Wednesday, Oct. 29, 2025. The Company will host an investor conference call at 10 a.m. ET on Thursday, Oct. 30, 2025, to discuss its results.
The conference call may be accessed by dialing 800-245-3047 and providing the conference ID EHCQ325. International callers should dial 203-518-9765 and provide the same conference ID. Please call approximately 10 minutes before the start of the call to ensure you are connected.
A live webcast of the conference call and an online replay of the conference call can be found on the Company's investor website at investor.encompasshealth.com.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 170 hospitals in 39 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is named America's Most Awarded Leader in Inpatient Rehabilitation by Newsweek and Statista and is ranked among Fortune's World's Most Admired Companies™ and Forbes' Most Trusted Companies in America. For more information, visit encompasshealth.com, or follow us on our newsroom, X, Instagram and Facebook.
From Fortune. © 2025 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World's Most Admired Companies™ is trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health. From Forbes © 2024 Forbes Media LLC. All rights reserved. Used under license.
Media contact:
Polly Manuel | 205-970-5912
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations contact:
Mark Miller | 205-970-5860
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$127.18 |
| Daily Change: | 1.05 0.83 |
| Daily Volume: | 574,211 |
| Market Cap: | US$12.810B |
August 07, 2025 August 04, 2025 June 18, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
